ArticleCommunications biology2026
Abnormal glycosylation of MUC20 mediates TAM polarization and promotes immune escape in colorectal cancer.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune evasion is one of the critical factors contributing to the advanced progression of colorectal cancer (CRC). Our research identified that CRC cells exhibit high expression of the zinc finger protein ZNF30, which transcriptionally activates the expression of the glycosyltransferase B4GALT2. B4GALT2 mediates the N-glycosylation of MUC20, which subsequently interacts with sialic acid-binding immunoglobulin-like lectin 7 (Siglec-7) on the surface of macrophages. This interaction induces M2 polarization of the macrophages, thereby promoting immune evasion in CRC and ultimately accelerating malignant progression. In vivo experiments also verified that the ZNF30/B4GALT2/MUC20 axis promotes the growth and metastasis of CRC. The discovery of this regulatory mechanism highlights the critical role of aberrant glycosylation of MUC20 in CRC immune evasion and offers new predictive markers and therapeutic targets for patients with advanced CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.